Table 4.

Treatment outcomes based on different body mass index before and after Botulinum toxin injection therapy.

	Normal weight 18.5 ≦ BMI<24 (n = 17 )	Overweight 24 ≦ BMI<27 (n = 15)	Obese 27 ≦ BMI (n = 13)	p
UDI-6
Pre-treatment	9.0 ± 3.7	8.4 ± 4.1	7.4 ± 3.1	0.519
Post-treatment	3.9 ± 3.8	5.4 ± 3.6	3.4 ± 1.5	0.182
Difference	− 4.3 ± 4.0	− 4.7 ± 4.6	− 3.8 ± 3.5	0.689
P (intergroup)	0.020	0.035	0.045
IIQ-7
Pre-treatment	12.1 ± 6.0	10.3 ± 6.7	11.7 ± 7.4	0.771
Post-treatment	5.4 ± 8.2	5.4 ± 5.7	5.5 ± 7.3	0.759
Difference	− 5.5 ± 7.9	− 8.0 ± 8.7	− 5.3 ± 7.8	0.808
P (intergroup)	0.050	0.035	0.142
OABSS
Pre-treatment	9.2 ± 2.9	10.1 ± 2.8	10.3 ± 3.7	0.121
Post-treatment	5.0 ± 4.0	6.1 ± 4.8	5.8 ± 3.7	0.540
Difference	− 3.9 ± 5.9	− 4.3 ± 4.8	− 4.4 ± 4.6	0.991
P (intergroup)	0.016	0.033	0.015
Micturition episodes
Pre-treatment	10.8 ± 5.0	8.6 ± 3.8	9.7 ± 4.1	0.400
Post-treatment	5.7 ± 3.7	7.3 ± 4.8	4.6 ± 1.7	0.350
Difference	− 4.6 ± 5.3	− 2.9 ± 6.4	− 6.8 ± 5.0	0.501
P (intergroup)	0.023	0.281	0.039
Nocturia episodes
Pre-treatment	2.8 ± 2.1	3.4 ± 1.6	3.1 ± 1.9	0.746
Post-treatment	1.6 ± 1.4	2.4 ± 1.6	1.5 ± 1.6	0.378
Difference	− 1.2 ± 1.1	− 1.6 ± 1.3	− 1.8 ± 2.0	0.264
P (intergroup)	0.036	0.017	0.079
Urgency episodes
Pre-treatment	6.0 ± 4.6	5.5 ± 3.8	7.9 ± 6.2	0.455
Post-treatment	2.4 ± 3.5	2.5 ± 3.1	1.8 ± 2.2	0.657
Difference	− 4.0 ± 5.2	− 5.1 ± 5.7	− 7.8 ± 6.0	0.301
P (intergroup)	0.044	0.047	0.043
Urinary incontinence episodes
Pre-treatment	3.4 ± 4.7	2.3 ± 1.9	2.2 ± 1.5	0.418
Post-treatment	0.6 ± 0.8	1.1 ± 1.3	0.8 ± 1.2	0.778
Difference	− 2.7 ± 13.0	− 2.0 ± 1.9	− 1.2 ± 2.4	0.810
P (intergroup)	0.038	0.027	0.324

Data are presented as mean ± standard deviation or as number (percent) of patients.

UDI-6: the short form of the Urogenital Distress Inventory, IIQ-7: the short form of the Incontinence Impact Questionnaire, OABSS: overactive bladder symptom score.